SONOSCAPE(SZ:300633) Xin Lang Cai Jing·2025-09-09 08:45Group 1 - The company maintains a cautious outperform rating, with a target price of 35.22 yuan, reflecting a 6% decrease from previous estimates [2] - For the first half of 2025, the company reported revenue of 964 million yuan, a year-on-year decline of 4.78%, and a net profit attributable to shareholders of 47 million yuan, down 72.43% year-on-year [2] - The company's Q2 2025 revenue was 534 million yuan, showing a slight year-on-year increase of 0.17%, while net profit decreased by 44.65% year-on-year to 39 million yuan [2] Group 2 - The company's ultrasound revenue for the first half of 2025 was 550 million yuan, down 9.87% year-on-year, with a gross margin of 57.31%, a decrease of 3.34 percentage points [2] - The endoscopy and related treatment devices revenue was 388 million yuan, showing a slight year-on-year increase of 0.08%, with a gross margin of 67.93%, down 4.17 percentage points [2] - As of June 30, 2025, the company reported accounts receivable of 190 million yuan, a decrease of 0.17%, and inventory of 788 million yuan, an increase of 4.47% [3]